Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...

Nubeqa Plus ADT Effective in mHSPC Regardless of Disease Volume ...

New advancements in cancer treatment are reducing the need for radical surgeries, offering organ-sparing therapies and ...

Living with follicular lymphoma, I challenge common misconceptions about cancer, highlighting the unique and varied ...

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in ...

New advancements in cancer treatment are reducing the need for radical surgeries, offering organ-sparing therapies and enhancing survivorship care and support for patients.

Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical ...

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung ...

As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung cancer research.

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 ...

The Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer ...

As cancer survivors, we all know how the dark times roll. We have gone through the shock of the diagnosis, facing the fear of ...